Yahoo Finance

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
Finanznachrichten

Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...